1. Home
  2. HOOD vs REGN Comparison

HOOD vs REGN Comparison

Compare HOOD & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOOD
  • REGN
  • Stock Information
  • Founded
  • HOOD 2013
  • REGN 1988
  • Country
  • HOOD United States
  • REGN United States
  • Employees
  • HOOD N/A
  • REGN N/A
  • Industry
  • HOOD Computer Software: Prepackaged Software
  • REGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • HOOD Technology
  • REGN Health Care
  • Exchange
  • HOOD Nasdaq
  • REGN Nasdaq
  • Market Cap
  • HOOD 54.5B
  • REGN 63.4B
  • IPO Year
  • HOOD 2021
  • REGN 1991
  • Fundamental
  • Price
  • HOOD $65.18
  • REGN $490.28
  • Analyst Decision
  • HOOD Buy
  • REGN Buy
  • Analyst Count
  • HOOD 21
  • REGN 23
  • Target Price
  • HOOD $61.95
  • REGN $891.17
  • AVG Volume (30 Days)
  • HOOD 36.4M
  • REGN 1.5M
  • Earning Date
  • HOOD 04-30-2025
  • REGN 04-29-2025
  • Dividend Yield
  • HOOD N/A
  • REGN 0.36%
  • EPS Growth
  • HOOD 1117.91
  • REGN 16.49
  • EPS
  • HOOD 1.75
  • REGN 39.43
  • Revenue
  • HOOD $3,260,000,000.00
  • REGN $14,085,700,000.00
  • Revenue This Year
  • HOOD $26.94
  • REGN N/A
  • Revenue Next Year
  • HOOD $15.64
  • REGN $6.97
  • P/E Ratio
  • HOOD $37.87
  • REGN $12.43
  • Revenue Growth
  • HOOD 59.65
  • REGN 7.52
  • 52 Week Low
  • HOOD $13.98
  • REGN $485.00
  • 52 Week High
  • HOOD $67.13
  • REGN $1,211.20
  • Technical
  • Relative Strength Index (RSI)
  • HOOD 65.21
  • REGN 32.32
  • Support Level
  • HOOD $62.63
  • REGN $590.15
  • Resistance Level
  • HOOD $67.13
  • REGN $608.17
  • Average True Range (ATR)
  • HOOD 2.78
  • REGN 18.79
  • MACD
  • HOOD -0.12
  • REGN -3.82
  • Stochastic Oscillator
  • HOOD 70.14
  • REGN 3.98

About HOOD Robinhood Markets Inc.

Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fraud detection, derivatives, fractional shares, recurring investments, and others.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: